[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100546348":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":24,"locations":29,"responsibleParty":45,"collaborators":10,"id":47,"slug":10,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":48,"sex":54,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":10,"studyType":60,"phases":10,"briefSummary":61,"conditions":62,"keywords":10,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"University Hospital, Brest","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Cancer patients treated for MVTE",null,"All the patients are included in one arm. They will undergo various type of samples.",[13],"Other: Collection of biological samples",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Collection of biological samples","Collecte of blood and urine samples",[9],[20],{"name":21,"affiliation":22,"role":23},"Françis Couturaud, Pr","CHU Brest","PRINCIPAL_INVESTIGATOR",[25],{"name":21,"role":26,"phone":27,"phoneExt":10,"email":28},"CONTACT","+33298347348","francis.couturaud@chu-brest.fr",[30],{"facility":31,"status":32,"city":33,"state":10,"zip":34,"country":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Brest University Hospital","RECRUITING","Brest","29200","France",{"type":37,"coordinates":38},"Point",[39,40],-4.48628,48.39029,{"lat":40,"lon":39},[43],{"name":44,"role":26,"phone":27,"phoneExt":10,"email":28},"Francis Couturaud, Prof",{"type":46,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100546348",false,"NCT06393764","Cancer-related Venous Thromboembolic Disease - Cohort Study","Establishment of a Patient-based Cohort : Cancer-related Venous Thromboembolic Disease.","CAPE","Inclusion Criteria:\n\n* Patients aged 18 years and more.\n* Patients with active cancer or requiring cancer treatment at the time of their VTE episode\n* Patients with documented VTE less than 2 years old\n* Patients affiliated to the social security system\n* Patient who has signed a written informed consent\n\nExclusion Criteria:\n\n* Patient under 18\n* Refusal to participate\n* Incapacity to consent to the study\n* Patient under guardianship\n* Incapacity to communicate (comprehension disorder)\n* Life expectancy of less than 6 months","ALL","18 Years","80 Years",{"count":58,"type":59},150,"ESTIMATED","OBSERVATIONAL","Venous thromboembolic disease (VTE) is a common (1\u002F1000), potentially serious disease (10% mortality when the clinical presentation is that of pulmonary embolism (PE)). In cancer patients, the risk of developing VTE is high and constitutes a negative prognostic factor for cancer; the risk of bleeding is also increased. The study of VTE in the context of cancer is a major challenge, given the frequency of the association, the heterogeneity of the situations, the risk factors involved and the therapeutic issues in both curative and primary prevention; in this field, many uncertainties remain, justifying a study focused on the association of VTE and cancer.",[63,64,65],"Thrombosis Embolism","Thromboses, Venous","Cancer","2026-06-12",{"date":68,"type":69},"2026-06-15","ACTUAL",{"date":71,"type":69},"2025-10-30",{"date":73,"type":59},"2035-10",{"name":5,"class":6},1]